SC
KYMR icon

Steven Cohen’s Kymera Therapeutics KYMR Stock Holding History

Steven Cohen’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-173,147
Closed -$13.5M – 4171
2025
Q4 		$13.5M Sell
173,147
-753
-0.4% -$50.8K 0.02% 1159
2025
Q3 		$9.84M Sell
173,900
-10,578
-6% -$477K 0.02% 805
2025
Q2 		$8.05M Buy
+184,478
New +$6.35M 0.02% 820
2023
Q4 		– Sell
-81,400
Closed -$1.13M – 2497
2023
Q3 		$1.13M Buy
+81,400
New +$1.64M ﹤0.01% 1290
2022
Q2 		– Sell
-652,800
Closed -$27.6M – 1520
2022
Q1 		$27.6M Buy
652,800
+594,600
+1,022% +$25.1M 0.11% 246
2021
Q4 		$3.69M Sell
58,200
-99,200
-63% -$5.78M 0.01% 732
2021
Q3 		$9.25M Buy
157,400
+89,800
+133% +$5.21M 0.04% 508
2021
Q2 		$3.28M Buy
+67,600
New +$2.93M 0.01% 678

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Steven Cohen's KYMR Position: Q1 2026 in Review

Steven Cohen sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 173,147 shares — an estimated $13.5M sold.

Steven Cohen first reported a position in KYMR in Q2 2021 and held it in 8 quarters. The position peaked at $27.6M in Q1 2022. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Steven Cohen reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Steven Cohen sold 173,147 Kymera Therapeutics shares in Q1 2026, an estimated $13.5M.
  • Steven Cohen first reported a position in Kymera Therapeutics in Q2 2021 and held it in 8 quarters.
  • Steven Cohen's Kymera Therapeutics position peaked at $27.6M in Q1 2022.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.